Results 131 to 140 of about 14,439 (224)

The role of biosimilars in value-based oncology care

open access: yes, 2018
Kashyap B Patel,1 Luiz H Arantes Jr,2 Wing Yu Tang,3 Selwyn Fung4 1Carolina Blood and Cancer Care, Rock Hill, SC, USA; 2Biosimilars Global Medical Affairs, Pfizer Essential Health, Pfizer Inc.
Patel KB, Tang WY, Arantes Jr LH, Fung S
core  

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars

open access: yesBiosensors
The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics.
Andrea Di Santo   +8 more
doaj   +1 more source

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China

open access: yesFrontiers in Public Health
BackgroundAs China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern.
Xin Du   +12 more
doaj   +1 more source

Is Australia positioned to take advantage of biosimilars?

open access: yes, 2014
Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small volume biological pharmaceuticals.
Lim, David (R19814)
core  

A QUM partnership approach to regulating biosimilars in Australia [PDF]

open access: yes, 2014
Despite the realisation of the potential implications from biosimilars is relatively recent, much has already been written about raising the awareness of differences between biosimilars and originating/ reference listed (innovator) pharmaceuticals.
Lim, David   +4 more
core  

Biosimilars and Switching: What Is Your Perspective?

open access: yesEuropean Medical Journal Rheumatology, 2017
The licensing of biosimilars heralds the start of a new era for physicians treating immune and inflammatory diseases. This symposium provided an update on biosimilar drugs and dealt with questions and concerns around switching from a reference biological
Sandoz
doaj  

Introducing New Biosimilars Into Current Treatment Algorithms [PDF]

open access: yes, 2016
Three biosimilar products are now licensed for the treatment of rheumatic diseases in Europe. The European Medicines Agency (EMA) requires that similarity between a biosimilar and its reference product is demonstrated using a rigorous, stepwise process ...
Tore K. Kvien   +3 more
core  

Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.

open access: yesPLoS ONE
ObjectiveTo evaluate the impact of the entry of biosimilars on the pricing of eight biologic products in 57 countries and regions.MethodsWe utilized an interrupted time series design and IQVIA MIDAS® data to analyze the annual sales data of eight ...
Hui-Han Chen   +2 more
doaj   +1 more source

Què són els medicaments biosimilars?

open access: yes
Medicaments biosimilars; Medicaments biològics; UtilitzacióMedicamentos biosimilares; Medicamentos biológicos; UtilizaciónBiosimilar medicines; Biological medicines; UseAquest article explica què són els medicaments biosimilars, quins tipus hi ha ...
Grup d'Informació sobre Medicaments Dirigida a la Ciutadania
core  

Home - About - Disclaimer - Privacy